NCT07478536
Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)
Not Yet Recruiting · Not specified · Insel Gruppe AG, University Hospital Bern · registry updated 2026-06-22
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The CHAS3 trial studies whether the Stockholm3 blood test can reliably detect if prostate cancer becomes more aggressive in men who are being carefully monitored instead of treated right away (active surveillance). The goal is to see if this test can help doctors safely follow patients with fewer invasive procedures, such as repeated biopsies.
Inclusion
- Adult Men ≥ 18 y. o.
- Men with low-risk prostate cancer (D'Amico risk classification) currently undergoing Active Surveillance (AS)
- First inclusion in Active Surveillance (AS) after 1st January 2022.
- Scheduled for follow-up with systematic and/or Magnetic Resonance Imaging (MRI)-targeted (fusion) prostate biopsies - Prostate Magnetic Resonance Imaging (MRI) performed within the past three months available
Exclusion
- \- Prior prostate cancer treatment (surgery, radiation, chemotherapy, hormonal therapy).
- Patient with intermediate- or high-risk prostate cancer
- Urinary catheterization within the past 6-8 weeks
- Contraindications to Magnetic Resonance Imaging (MRI) or biopsy